Kornimate/medical-research-clean huggingface dataset:
instrument based fascial abrasion versus myofascial release technique in cervicogenic headache patients

Conditions: Cervicogenic Headache

Summary: study will be randomized clinical trial. data will be collected from non probability consecutive sampling technique. total 44 participants from rafiqa hospital and district headquarter (dhq) sargodha will be selected and randomly allocated to two different groups i.e group a and group b. group a will be treated with instrument assisted fascial abrasion and conventional therapy for 5 minutes, 6 sessions (3 sessions per week) (12) while group b will be treated with myofascial release technique and conventional therapy for 2 to 3 minutes, 5-7 repetitions and 3 sessions per week on alternate days were given for 6 weeks. nprs, mos-36, ndi will be used as outcome measuring tool before and after treatment. data will be analyzed by using statistical package for social sciences 25.

cervicogenic headache is a symptomatic headache characterized by chronic, hemi cranial pain syndrome in which pain sensations originates in cervical spine and soft tissues of the neck and basically referred to head. cervicogenic headache originates in the upper cervical region, and the headache mechanism involves nociceptive structures such as the upper cervical spinal nerves, ganglia, disks, facet joints, muscles, and ligaments. consequently, the anatomical structures innervated by cervical roots c1-c3 are potential sources of cervicogenic headache. myofascial release (mfr) is a therapeutic technique that uses gentle pressure and stretching (in both forms of direct and indirect approaches) with the intention of restoring decrease pain, optimizing length and facilitating the release of fascial restrictions caused by injury, stress, repetitive use, etc. there are some studies about mfr and its effects which include: increase extensibilities of soft tissues, increase rom, improves joint biomechanics, increases temperature of fascia, increases blood circulation to the muscles and decreases pain and muscles tone significantly. although; a lot of remedies such as physiotherapy, electrotherapy, exercises therapy and spinal mobilization are used for cervicogenic headache, but sub-occipital mfr for cervicogenic headache has not been studied specifically. another technique used for cervicogenic headache includes fascial abrasion technique tool that is a revolutionary tool that can quickly and effectively loosen muscle tissue/fascia. it improves range and quality of movement.

Eligibility criteria:
inclusion criteria: * patients having headaches with neck stiffness and pain. * headache for the past 3 months at least once per week. * positive flexion rotation test and restriction greater than 10° * patient aged 18-66 years old. exclusion criteria: * headache not of cervical origin. * physiotherapy or chiropractic treatment in the past 3 months. * headache with autonomic involvement, dizziness and visual disturbance. * congenital conditions of cervical spine

Keywords: neck and head pain
levitra® specific drug use investigation. to investigate the safety profile in combination use with alpha-blockers

Conditions: Erectile Dysfunction

Summary: main object is to investigate the safety profile of levitra in combination use with alpha-blockers in patients with erectile dysfunction used in clinical practice after launch. in the initial combination date and the first and second observation after initial combination date, number of tablets prescribed, dose of tablets and number of tablets taken until follow-up visit will be investigated. the efficacy and tolerability will be evaluated at 2 months after initial combination date.


Eligibility criteria:
inclusion criteria: * patients \>/= 18 years * enrollment within 7 days after initiation of combination use of levitra and alpha-blockers exclusion criteria:

Keywords: vardenafil erectile dysfunction phosphodiesterase inhibitors combination use with alpha-blockers
mri guided high intensity focused ultrasound (hifu) and thermodox for palliation of painful bone metastases

Conditions: Painful Bone Metastases; Breast Carcinoma; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Adenocarcinoma

Summary: this study will evaluate treatment with high intensity focused ultrasound (hifu)in combination with thermodox (liposomal doxorubicin) is safe and effective in reducing pain for patients with painful bone metastases.


Eligibility criteria:
inclusion criteria: * histological confirmation of breast carcinoma, non-small cell lung cancer, small cell lung cancer, or adenocarcinoma of the prostate * bone metastases index lesion in the ribs, clavicle, scapula, upper extremities, pelvis, or posterior aspects of the lumbar vertebra l3-l5 or sacral s1-s5. * patients will have failed at least one prior attempt or will not be eligible for external beam radiation therapy (ebrt) exclusion criteria: * greater than 450 mg/m2 of prior free doxorubicin and/or non-heat activated liposomal doxorubicin * lvef \< 50% * significant cardiac history * brain metastases * contraindication for mr imaging (as incompatible implanted metallic device, weight \>250 lbs etc) or known intolerance or allergy to mri contrast agents.

Keywords: painful bone metastases bone cancer bone cancer pain patients with
mapping and characterization of alveolar cells during smoking and chronic obstructive disease

Conditions: Chronic Obstructive Lung Disease; Chronic Obstructive Pulmonary Disease

Summary: to evaluate the regenerative capacities of mesenchymal cells composing the microenvironment of alveolar type 2 cells in a population of patients, undergoing thoracic surgery for suspected cancer, who are smokers with and without copd compared to non-smokers patients

chronic obstructive pulmonary diseases (copd) have a major public health impact, as evidenced by the 250 million patients affected by these diseases and the 50% 5-year mortality for severe stages of chronic obstructive pulmonary disease (copd). one pathophysiological mechanism of copd and emphysema is a depletion of alveolar progenitor cells inducing a loss of alveolar-reparation capacities after an aggression. the genesis of these alterations and the mechanisms involved remain unknown. alveolar type 2 cells (at2) are the alveolar epithelial progenitor cells. at2 proliferate and differentiate into alveolar type 1 cells (at1) which form the alveolar-capillary barrier, along with endothelial cells, through which respiratory gas exchanges take place. the proliferation and differentiation of at2 into at1 are under the control of mesenchymal cells and endothelial cells located in close proximity. together these cells form the alveolar stem cell niche. the characteristics and interactions of the different cell populations have been well described during lung growth, in the normal adult lung or during pulmonary fibrosis; however, participants are poorly described during smoking exposure and chronic obstructive diseases.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 2. patient undergoing lung resection surgery (lobectomy, pneumonectomy, segmentectomy) for cancer or suspected cancer 3. acceptance to participate in the protocol 4. affiliated to a social security plan exclusion criteria: 1. chronic autoimmune disease 2. patient under guardianship or curators 3. neo-adjuvant chemotherapy 4. history of thoracic radiotherapy 5. pregnant woman 6. minor patient 7. person not able to consent 8. person deprived of liberty
influence of treatment duration and stimulation frequency on rtms in chronic tinnitus

Conditions: Chronic Tinnitus

Summary: patients receive two weeks of treatment (prefrontal high-frequency and bilateral low-frequency rtms vs. prefrontal high-frequency and bilateral high-frequency rtms). after two weeks of treatment they can decide if they want to quit the treatment or if they want to proceed with the treatment for another two weeks.

tinnitus is the phantom auditory perception of sound in the absence of an external or internal acoustic stimulus. it is a frequent problem which can interfere significantly with the ability to lead a normal life. tinnitus has been shown to be generated in the brain, as a result of functional reorganization of auditory and non-auditory neural pathways. low-frequency repetitive transcranial magnetic stimulation (rtms) applied to the temporoparietal areas has been investigated for the treatment of tinnitus based on the rationale to reduce increased activity of the auditory system. furthermore, high-frequency stimulation of the left frontal cortex was added to this standard treatment based on rtms studies in affective disorders and the association of tinnitus distress with depressivity. thus, high-frequency stimulation of the left prefrontal cortex and low-frequency stimulation of bilateral temporoparietal cortex was introduced as new treatment scheme in chronic tinnitus (multisite standard). additionally, there is also evidence that high-frequency stimulation of the temporoparietal cortex is effective in chronic tinnitus. furthermore, standard treatment in chronic tinnitus is two weeks (ten treatment days) which is shorter than the standard in rtms in affective disorders. thus, the aim of the present trial is to investigate the influence of high-frequency stimulation of the temporoparietal cortex and of increasing the number of treatment days. patients receive two weeks of treatment (prefrontal high-frequency and bilateral low-frequency rtms vs. prefrontal high-frequency and bilateral high-frequency rtms). after two weeks of treatment they can decide if they want to quit the treatment or if they want to proceed with the treatment for another two weeks.

Eligibility criteria:
inclusion criteria: * written informed consent * duration of tinnitus more than 6 months * bothersome chronic tinnitus exclusion criteria: * not stable internal, mental, and neurological diseases * contraindication for rtms (pacemaker, metal implants, pregnancy, epilepsy, status post severe craniocerebral injury ) * uninvolvement in other treatment studies for tinnitus at the same time

Keywords: tinnitus transcranial random noise stimulation rtms multisite stimulation non-invasive brain stimulation
classification and longitudinal follow-up of common melanocytic nevi with in vivo reflectance confocal microscopy

Conditions: Common Melanocytic Nevi

Summary: our working hypothesis is that reflectance confocal microscopy (rcm) can identify distinct subsets of melanocytic nevi that retain their distinctive pattern over time.


Eligibility criteria:
inclusion criteria: * patients visiting the sheba medical center pigmented lesion clinic for skin examination * patients having at least three banal-appearing nevi, one on the upper back, one on the lower back and one on the lower extremity (excluding foot), which are amenable for rcm examination. exclusion criteria: * patients who are unwilling or medically unable to lie down for 30 minutes. * pregnant women

Keywords: banal-appearing nevi nevus
study of covalently closed circular dna (cccdna) in liver transplant patients with b virus markers

Conditions: Liver Transplantation

Summary: the aim of this study is to validate in the context of liver transplantation, the interest of the cccdna assay technique developed by the team of professor zoulim (inserm u1052) on liver biopsy and correlate this assay cccdna in hepatitis b virus (hbv) viral load and serum liver through several groups of patients at transplantation (on graft and native liver explant) and after transplantation.


Eligibility criteria:
inclusion criteria: * patient registered on the national organ transplant waiting list for liver transplantation * indication of transplantation : * alcoholic related disease without serum anti-hepatitis b core antibody (hbc) (less than 4 weeks) or - hcv related disease without serum anti-hbc antibody (less than 4 weeks) or - patients who sign consent for liver transplantation from hepatitis b core antibody positive donors or - hbv related disease with positive serum hbs antigen (with or without hbv replication measured by polymerase chain reaction (pcr) within 6 months prior transplantation) * signed consent form * patient with a social cover * patient not covered by any measure of legal protection exclusion criteria: * co-infection with hiv, hepatitis delta virus (hdv), hbv (for control arm), hcv (for test arm) - positive serology within the4 weeks before inclusion * patient covered by any measure of legal protection * informed consent not signed

Keywords: liver transplantation hbv cccdna
restless leg syndrome and severe preeclampsia

Conditions: Restless Leg Syndrome; Severe Preeclampsia

Summary: restless leg syndrome is a common but not well recognized central nervous system disorder. it is more prevalent during pregnancy and, if present before pregnancy, can develop an exacerbation of symptoms. in some of the hypothesis trying to explain this syndrome, the physiopathology can also explain hypertensive disorders of pregnancy. so far, no study has been done trying to link both disorders.


Eligibility criteria:
inclusion criteria: * gestational age between 24-34 weeks * severe preeclampsia exclusion criteria: * neurological disorders (central nervous system)

Keywords: restless leg syndrome severe preeclampsia
acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs immune checkpoint inhibitors

Conditions: AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs

Summary: the goal of this a retrospective real-world study is to compare the aki events in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (antivegf) vs immune checkpoint inhibitors (icis). the main question it aims to answer is whether the choice between antivegf and icis affects the risks of acute kidney injury in cancer patients. cancer patients receiving antivegf will be compared to those treated with icis to see if the aki incidence is higher in patients receiving icis.


Eligibility criteria:
inclusion criteria: * age \>=20yr; * patients must have at least one "evaluation and management"visit with a diagnosis of cancer within 12 months before index date (in situ biopsy will not be required, since patients may receive a diagnosis from a biopsy of metastatic site); * indication to initiate antivegf or icis exclusion criteria: * patients without valid data and less than 3 months followup; * patients without baseline scr value within 12 mon before index date; * patients with combination therapy of anti-vegf and icis ; * patients with chronic renal failure
open-label study of uridine triacetate in pediatric patients with hereditary orotic aciduria

Conditions: Hereditary Orotic Aciduria

Summary: this protocol has two parts - the main study which is 42 days in length and the treatment extension which allows the patients who complete the main study to continue receiving treatment with uridine triacetate. the purpose of this study is to replace oral administration of uridine with oral administration of uridine triacetate in patients with hereditary orotic aciduria who have received (or would reasonably be expected to receive) clinical benefit from treatment with exogenous uridine. it is also to document the continued clinical benefit of exogenous uridine when patients are switched from oral administration of uridine to oral administration of uridine triacetate.

data to be collected during the main study include demographic, baseline disease information and medical history including all prior disease-directed therapy. in addition, vital signs, laboratory values and adverse events information will be collected and recorded. urine samples will be obtained and measured for orotic acid and orotidine levels. systemic levels of uridine will be evaluated from plasma samples collected at set timepoints. upon successful completion of the main study and entry into the treatment extension, physical exams and vital signs will be performed every six (6) months. additionally, plasma samples to measure systemic levels of uridine and urine samples to measure levels of orotic acid and orotidine will be collected every (6) six months.

Eligibility criteria:
inclusion criteria (main study): * patients with diagnosed hereditary orotic aciduria * judged by the investigator to have the initiative and means to be compliant with the protocol * able to take oral medications * able to provide written informed consent (patient or legally authorized representative) * females of childbearing potential must have a negative pregnancy test at screening * females of childbearing potential or males with partners of childbearing potential are to use one of the following acceptable birth control methods: * surgically sterile or partner is surgically sterile * using adequate contraception (hormonal contraceptives, double barrier methods, or intra-uterine devices) * patients who claim to be sexually inactive agree to use an acceptable method of contraception should she or he become sexually active from 14 days prior to first dosing, throughout the study and for 14 days after the last dose administration exclusion criteria (main study): * has a known allergy to uridine triacetate or any of its excipients * known to have ornithine transcarbamoylase deficiency * unable to have the initiative and means to be compliant with the protocol * unable to be compliant with taking oral medications * unable to provide written informed consent (patient or legally authorized representative) * female who is pregnant or lactating inclusion criteria (treatment extension) * patient successfully completed the main study exclusion criteria (treatment extension) * patient did not successfully complete the main study
ursodeoxycholic acid (udca) as a neuroprotective adjuvant treatment to rhegmatogenous retinal detachment surgery

Conditions: Retinal Detachment

Summary: this study is indicated for patients with extended rhegmatogenous retinal detachment (rrd) (≥ 2 quadrants) with macula off lasting 7 days or less, pseudophakic or aphakic, and scheduled to undergo surgical intervention with vitrectomy and gas tamponade in one of the ophthalmology departments participating in the study. the main objective is to assess the effectiveness of udca in visual acuity recovery at 3 months (i.e., the difference between preoperative visual acuity and visual acuity 3 months after surgery) in pseudophakic or aphakic patients who have undergone successful surgical intervention (reattachment of the retina) through vitrectomy and gas tamponade following rhegmatogenous retinal detachment (rrd). 120 patients will be enrolled and randomized in two groups: * the experimental arm "udca group," with oral administration of ursodeoxycholic acid (ursolvan®) * the control group "placebo group," with oral administration of the placebo.


Eligibility criteria:
inclusion criteria: 1. aged 18 years or older, 2. scheduled to undergo surgical intervention through vitrectomy, 3. aphakic or pseudophakic patients, 4. experiencing rhegmatogenous retinal detachment affecting 2 quadrants or more, 5. presenting with macula off (raised macula) for 7 days or less before the onset of symptoms, 6. has signed a consent form, 7. affiliated with a health insurance plan. exclusion criteria: 1. patients who have previously undergone vitrectomy for retinal detachment, 2. patients with vitreous hemorrhage or any other associated retinal pathologies, 3. monophthalmic patients, 4. women of childbearing age without effective contraceptive methods, 5. pregnant or lactating women, 6. hypersensitivity to the active substance, bile acids, or any of the excipients in ursolvan® (see §6.1.1 of this protocol), 7. patients with peptic ulcers, acute or chronic liver disease, acute infection or inflammation of the gallbladder or bile ducts, recurrent gallstones, or obstruction of the bile ducts (common bile duct or cystic duct obstruction), 8. patients with radiopaque calcified gallstones, 9. patients with severe pancreatic disorders, 10. patients with crohn's disease, ulcerative colitis, or other intestinal diseases that may alter the enterohepatic circulation of bile acids, 11. patients on oral treatment with cholestyramine, colestipol, antacids containing aluminum or magnesium hydroxide and/or smectite (aluminum oxide), cyclosporine, ciprofloxacin, nitrendipine, or dapsone, 12. patients with galactose intolerance, lapp lactase deficiency, or glucose and galactose malabsorption syndrome (rare hereditary diseases), 13. patients participating or in the exclusion period following an interventional research with the use of prohibited medications in this study, 14. patients under protective custody.
evaluation of screening methods for treatment of meibomian gland dysfunction

Conditions: Chalazion; Dry Eye Syndromes

Summary: the objective is to evaluate the feasibility of using additional screening methods to optimize effectiveness outcomes with the lipiflow system for application of heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye, and chalazia. the screening methods include diagnostic expression of the meibomian glands and interferometry assessment of the tear film.


Eligibility criteria:
inclusion criteria: * meibomian gland dysfunction * dry eye symptoms exclusion criteria: * ocular surgery, ocular injury or ocular herpes infection within past 3 months * active ocular infection * active ocular inflammation or recurrent inflammation within past 3 months * moderate to severe allergic conjunctivitis * severe eyelid inflammation * eyelid abnormalities that affect lid function * ocular surface abnormalities that may compromise corneal integrity * systemic disease conditions or medications that cause dry eye * use of other treatments for meibomian gland dysfunction or dry eye * pregnant or nursing women * participation in another ophthalmic clinical trial within past 30 days